ONC212, inhibitor
ONC212
Purity
98.00%
Synonyms
ONC212; inhibitor
Purity/Purification
98.00%
Form/Format
Powder
Formula
C24H23F3N4O
CAS
1807861-48-8
Smiles
FC(F)(F)c1ccc(CN2C3=NCCN3C3=C(CN(Cc4ccccc4)CC3)C2=O)cc1
Receptor (IC50)
GPR132
Solubility
DMSO: 50mg/mL (113.52mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)
Preparation and Storage
Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent
For obtaining a higher solubility, please warm the tube at 37 degree C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 degree C for several month.
For obtaining a higher solubility, please warm the tube at 37 degree C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 degree C for several month.
Structure
Related Product Information for ONC212, inhibitor
ONC212, a fluorinated-ONC201 analogue, is a selective agonist of GPR132.
References
1. Nii T, Prabhu VV, Ruvolo V,et al.Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia[J].Leukemia. 2019 Dec;33 (12):2805-2816.
2. Lev A, Lulla A R, Wagner J, et al. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.[J]. Oncotarget, 2017, 8 (47):81776-81793.
3. Takenobu Nii, et al. The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199. ASH. 2017.
4. Wagner J, et al. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16 (19):1790-1799.
2. Lev A, Lulla A R, Wagner J, et al. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.[J]. Oncotarget, 2017, 8 (47):81776-81793.
3. Takenobu Nii, et al. The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199. ASH. 2017.
4. Wagner J, et al. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16 (19):1790-1799.
